Results 191 to 200 of about 7,414,900 (347)

Characterization of lipid-poor adrenal adenoma: chemical-shift MRI and washout CT.

open access: yesAJR. American journal of roentgenology, 2014
Jung Min Seo   +3 more
semanticscholar   +1 more source

Peroxidasin enables melanoma immune escape by inhibiting natural killer cell cytotoxicity

open access: yesMolecular Oncology, EarlyView.
Peroxidasin (PXDN) is secreted by melanoma cells and binds the NK cell receptor NKG2D, thereby suppressing NK cell activation and cytotoxicity. PXDN depletion restores NKG2D signaling and enables effective NK cell–mediated melanoma killing. These findings identify PXDN as a previously unrecognized immune evasion factor and a potential target to improve
Hsu‐Min Sung   +17 more
wiley   +1 more source

Chemical shift-encoded multishot EPI for navigator-free prostate DWI. [PDF]

open access: yesMagn Reson Med
Dong Y   +4 more
europepmc   +1 more source

Quantitative chemical shift‐encoded MRI is an accurate method to quantify hepatic steatosis

open access: yesJournal of Magnetic Resonance Imaging, 2014
J. Kühn   +7 more
semanticscholar   +1 more source

Redox regulation meets metabolism: targeting PRDX2 to prevent hepatocellular carcinoma

open access: yesMolecular Oncology, EarlyView.
PRDX2 acts as a central redox hub linking metabolic dysfunction‐associated steatohepatitis (MASH) to hepatocellular carcinoma (HCC). In normal hepatocytes, PRDX2 maintains redox balance and metabolic homeostasis under oxidative stress. In contrast, during malignant transformation, PRDX2 promotes oncogenic signaling, stemness, and tumor initiation ...
Naroa Goikoetxea‐Usandizaga   +2 more
wiley   +1 more source

On the confounding effect of temperature on chemical shift‐encoded fat quantification

open access: yesMagnetic Resonance in Medicine, 2014
D. Hernando   +3 more
semanticscholar   +1 more source

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

open access: yesMolecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy